VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination to Advance Next-Generation Cancer Therapies

VERAXA Biotech and Voyager Acquisition Corp. announced a business combination to develop next-generation cancer therapies, targeting a $1.3 billion valuation. https://www.nasdaq.com/articles/veraxa-biotech-and-voyager-acquisition-corp-announce-business-combination-advance-next